Trade around ESMO presentation on October 24, 2026. If data are positive (meaningful PFS/OS improvement vs paclitaxel alone), CMPX could see a substantial upside given its early-stage profile and $378M market cap. Pre-positioning carries binary risk; monitor for abstract or top-line release before the conference.
Price Chart
Executive Summary
Compass Therapeutics announces that its Phase 2/3 COMPANION-002 trial of tovecimig + paclitaxel in advanced biliary tract cancer (BTC) has been accepted for an oral Proffered Paper presentation at ESMO 2026 (Oct 23-27, Madrid). This is a key catalyst event for a clinical-stage biotech with no approved products, as tovecimig is a DLL4 x VEGF-A bispecific antibody addressing an area of high unmet need.
Key Facts
- Phase 2/3 COMPANION-002 trial of tovecimig + paclitaxel in advanced BTC accepted for oral presentation at ESMO Congress (Oct 23-27, 2026, Madrid).
- Presentation by Dr. Nilofer Azad (Johns Hopkins) on Saturday, October 24, 2026.
- Tovecimig is a DLL4 x VEGF-A bispecific antibody targeting angiogenesis and immune activation.
- Compass Therapeutics has a $378M market cap and no commercial-stage assets.
Financial Impact
Event-driven catalyst; magnitude depends on data outcomes. Positive data could significantly increase valuation for this clinical-stage biotech.
Risk Factors
- Data may fail to show statistical significance or clinical meaningfulness.
- Competing BTC therapies (pembrolizumab, durvalumab + chemo) could limit commercial potential even with positive data.
- Compass will need additional funding to advance tovecimig to commercialization.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3329171 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 24, 2026 3d ago | Press Release | $0.7472 | awaiting T+20 | — | $0.7470 (−0.03%) |
Sep 22, 2026 5w ago | 8-K | $1.24 $0.8330 | ▲ +32.82% | ▲ +32.26% | $0.7470 (+39.76%) |
Aug 21, 2026 9w ago | Institutional Cluster | $2.40 $1.90 | ▼ −20.83% | ▼ −20.55% | $0.7470 (−68.88%) |
Aug 6, 2026 11w ago | 8-K | $1.99 $2.37 | ▲ +19.10% | ▲ +18.50% | $0.7470 (−62.46%) |
Aug 6, 2026 11w ago | Press Release | $1.99 $2.37 | ▲ +19.10% | ▲ +18.50% | $0.7470 (−62.46%) |
Jul 17, 2026 14w ago | Press Release | $2.05 $2.25 | ▲ +9.76% | ▲ +5.31% | $0.7470 (−63.56%) |
Jul 1, 2026 16w ago | 8-K | $2.27 $1.94 | ▼ −14.54% | ▼ −14.12% | $0.7470 (−67.09%) |
Jun 11, 2026 19w ago | Institutional Cluster | $2.03 $2.33 | ▲ +14.78% | ▲ +13.00% | $0.7470 (−63.20%) |
May 21, 2026 22w ago | Press Release | $2.07 $2.09 | ▲ +0.72% | ▲ +2.14% | $0.7470 (−63.91%) |
May 5, 2026 25w ago | 8-K | $1.95 $2.08 | ▲ +6.67% | ▲ +1.71% | $0.7470 (−61.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers